10x Genomics, Inc. (NASDAQ:TXG) Stock Position Reduced by Raymond James & Associates

Raymond James & Associates lessened its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 10.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,270 shares of the company’s stock after selling 873 shares during the period. Raymond James & Associates’ holdings in 10x Genomics were worth $407,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of 10x Genomics by 56.4% in the 3rd quarter. FMR LLC now owns 12,666,998 shares of the company’s stock worth $522,514,000 after purchasing an additional 4,565,400 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of 10x Genomics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 8,903,517 shares of the company’s stock worth $367,270,000 after purchasing an additional 354,921 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of 10x Genomics by 18.9% in the 3rd quarter. Invesco Ltd. now owns 2,226,466 shares of the company’s stock worth $91,842,000 after purchasing an additional 354,680 shares during the last quarter. Bamco Inc. NY lifted its holdings in shares of 10x Genomics by 554.9% in the 3rd quarter. Bamco Inc. NY now owns 180,926 shares of the company’s stock worth $7,463,000 after purchasing an additional 153,300 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of 10x Genomics by 13.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,010,256 shares of the company’s stock worth $41,673,000 after purchasing an additional 122,981 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on TXG shares. Barclays cut their price target on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft cut their price target on 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Finally, Stifel Nicolaus lowered their target price on 10x Genomics from $68.00 to $63.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $60.22.

10x Genomics Price Performance

TXG opened at $27.59 on Friday. 10x Genomics, Inc. has a 12 month low of $26.30 and a 12 month high of $63.57. The stock has a market cap of $3.29 billion, a P/E ratio of -12.71 and a beta of 1.90. The stock’s 50 day moving average price is $37.70 and its 200 day moving average price is $42.53.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The firm had revenue of $183.98 million for the quarter, compared to analyst estimates of $182.73 million. During the same quarter last year, the business posted ($0.15) earnings per share. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. Equities analysts anticipate that 10x Genomics, Inc. will post -1.47 EPS for the current year.

Insider Activity

In other news, CEO Serge Saxonov sold 1,000 shares of 10x Genomics stock in a transaction on Friday, February 9th. The stock was sold at an average price of $49.53, for a total transaction of $49,530.00. Following the transaction, the chief executive officer now directly owns 855,381 shares in the company, valued at approximately $42,367,020.93. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Serge Saxonov sold 1,000 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $49.53, for a total transaction of $49,530.00. Following the completion of the sale, the chief executive officer now directly owns 855,381 shares of the company’s stock, valued at approximately $42,367,020.93. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 2,613 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $121,086.42. Following the sale, the insider now directly owns 283,059 shares of the company’s stock, valued at $13,116,954.06. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,959 shares of company stock worth $592,806. 10.65% of the stock is owned by company insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.